Biomerica's inFoods® IBS Test Receives Key CPT® PLA Code: A Game Changer for IBS Diagnostics

IRVINE, Calif., July 02, 2025 – Biomerica, Inc. (NASDAQ: BMRA), a leading global biomedical company dedicated to advancing gastroenterology diagnostics, today announced a significant milestone: the American Medical Association (AMA) CPT editorial panel has issued a Current Procedural Terminology (CPT®) code within the Proprietary Laboratory Analysis (PLA) code category for the Company's innovative inFoods® IBS test. This pivotal development is expected to dramatically enhance the accessibility and reimbursement potential for Biomerica's groundbreaking diagnostic solution, which aims to identify specific food sensitivities contributing to Irritable Bowel Syndrome (IBS) symptoms.

The assignment of a dedicated CPT® PLA code is a critical step in the commercialization pathway for novel laboratory tests. It provides a standardized mechanism for healthcare providers to bill for the inFoods® IBS test, facilitating smoother reimbursement from insurance payers. This recognition by the AMA underscores the medical community's acknowledgment of the test's clinical utility and its potential to improve patient outcomes for the millions suffering from IBS worldwide. IBS affects an estimated 10-15% of the global population, yet diagnosis and effective management remain challenging, often involving trial-and-error dietary restrictions.

Understanding the Impact of a CPT® PLA Code

• Enhanced Reimbursement: A CPT® PLA code streamlines the billing process, making it easier for laboratories and healthcare providers to receive payment for the inFoods® IBS test. This clarity in billing is crucial for widespread adoption.
• Increased Accessibility: With clearer reimbursement pathways, more physicians are likely to offer the test, increasing patient access to this innovative diagnostic tool.
• Clinical Validation: The AMA's decision to issue a CPT® code signifies a level of clinical validation and acceptance within the medical community, bolstering confidence in the test's efficacy and reliability.
• Market Penetration: This code is a key enabler for Biomerica to penetrate the vast IBS diagnostic market more effectively, potentially accelerating revenue growth.

Biomerica's inFoods® IBS test is designed to identify specific food intolerances that can trigger IBS symptoms, moving beyond general dietary advice to provide personalized insights. By pinpointing these triggers, the test empowers patients and their healthcare providers to develop targeted dietary plans, potentially leading to significant symptom relief and improved quality of life. This personalized medicine approach represents a significant advancement over traditional, often less effective, diagnostic and management strategies for IBS.

Market Context and Investment Implications

The global market for IBS diagnostics and therapeutics is substantial and growing, driven by increasing prevalence rates and a greater understanding of the condition. Biomerica's inFoods® IBS test is positioned to capture a significant share of the diagnostic segment by offering a unique, actionable solution. The receipt of a CPT® PLA code is a strong positive signal for investors, indicating that a major hurdle to commercial success has been cleared. This development could lead to accelerated adoption rates and, consequently, a positive impact on Biomerica's financial performance.

For investors, this news suggests a de-risking event for BMRA. While the full financial impact will depend on adoption rates and reimbursement levels, the CPT® code significantly improves the test's commercial viability. Investors should monitor Biomerica's upcoming earnings reports for updates on the rollout and uptake of the inFoods® IBS test. This development reinforces Biomerica's position as an innovator in the gastroenterology space and highlights the company's commitment to bringing clinically valuable diagnostics to market.

Looking Ahead

Biomerica is now well-positioned to capitalize on the growing demand for advanced IBS diagnostics. The company's focus on innovative, patient-centric solutions continues to drive its growth strategy. The inFoods® IBS test, with its newly assigned CPT® PLA code, is poised to become a cornerstone of personalized IBS management, offering hope and relief to millions of patients and creating significant value for shareholders. This achievement underscores Biomerica's dedication to improving digestive health through scientific innovation and strategic market access initiatives.